Ocular Therapeutix™ to Participate in September Investor and Scientific Conferences

Core Viewpoint - Ocular Therapeutix, Inc. is actively participating in several investor and scientific conferences in September 2025 to showcase its advancements in retinal therapies and engage with the investment community [1][2][3]. Upcoming Investor Conferences - Ocular Therapeutix will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, from 2:35 to 3:10 PM ET, with Dr. Pravin U. Dugel as the presenter [2]. - The company will also participate in the Baird 2025 Global Healthcare Conference on September 9, 2025, from 12:50 to 1:20 PM ET, again featuring Dr. Pravin U. Dugel [2]. - Live webcasts of these presentations will be available on the Ocular Therapeutix website, with replays archived for at least 30 days [2]. Upcoming Scientific Conferences - Ocular Therapeutix will present at the EURETINA Innovation Spotlight on September 3, 2025, in Paris, focusing on redefining the retina experience, with Dr. Peter K. Kaiser as the presenter [3]. - The company will also participate in the Ophthalmology Futures Forums Retina Forum on the same day, with Dr. Peter K. Kaiser presenting in two sessions [4][5]. - At the 25th EURETINA Congress from September 4-7, 2025, Ocular will host a symposium titled "Advancing Retinal Disease Treatment: Exploring OTX-TKI's Potential to Extend Treatment Durability" on September 6, 2025 [5]. Company Overview - Ocular Therapeutix is an integrated biopharmaceutical company focused on redefining the retina experience, with its investigational product AXPAXLI™ (OTX-TKI) currently in Phase 3 clinical trials for wet age-related macular degeneration [8]. - The company also leverages its proprietary ELUTYX™ technology in its commercial product DEXTENZA, an FDA-approved corticosteroid for treating ocular inflammation and pain, and in its investigational product OTX-TIC, currently in Phase 2 trials for open-angle glaucoma [9].